Bert L. Lum

5.8k citations

83 papers · 4.7k indexed · h-index 38

Impact in

Oncology top 1%
- Drug Transport and Resistance Mechanisms
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
Hematology top 2%

Papers in

Oncology 50
- HER2/EGFR in Cancer Research 16
- Drug Transport and Resistance Mechanisms 13
- Colorectal Cancer Treatments and Studies 10
- Peptidase Inhibition and Analysis 9
- Cancer Treatment and Pharmacology 6
Pharmacy 4

Co-authors: Branimir I. Šikić Michael P. Gosland Frank M. Torti William Novotny Ashok Rakhit Marta Hamilton Sonja Kaubisch Steve Eppler
Journals: Cancer Chemotherapy and Pharmacology (16 papers)Cancer (6 papers)Anti-Cancer Drugs (5 papers)Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (4 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Bert L. Lum

83 papers receiving 4.5k citations

Peers

Countries citing papers authored by Bert L. Lum

Since Specialization

Citations

This map shows the geographic impact of Bert L. Lum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert L. Lum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert L. Lum more than expected).

Fields of papers citing papers by Bert L. Lum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert L. Lum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert L. Lum. The network helps show where Bert L. Lum may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bert L. Lum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bert L. Lum Line = papers co-authored together Bert L. Lum links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study Cancer Chemotherapy and Pharmacology ·Na Xu, Charles H. Redfern, Michael S. Gordon, Stephen Eppler, Bert L. Lum, Arthur Lafarge	2014	6
2	The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects Cancer Chemotherapy and Pharmacology ·Marta Hamilton, Julie Wolf, Daniel W. Drolet, Scott Fettner, Ashok Rakhit, Karsten Witt, Bert L. Lum	2014	41
3	Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males Cancer Chemotherapy and Pharmacology ·Chris Wynne, R. B. Ellis‐Pegler, Caterina Ottobrini, Christian Schwabe, Michaela Lehle, Dominik Heinzmann, 現代日本経済史研究会, Chunze Li, 青晓, Georgina Aisbitt, Bert L. Lum	2013	19
4	Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects British Journal of Clinical Pharmacology ·Richard Graham, Cornelis E. C. A. Hop, Marie T. Borin, Bert L. Lum, Dawn Colburn, Ilsung Chang, Young G. Shin, Vikram Malhi, Jennifer A. Low, Mark J. Dresser	2012	49
5	Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding Clinical Cancer Research ·Richard Graham, Bert L. Lum, Sravanthi Cheeti, Jin Y. Jin, Karin Jorga, Daniel D. Von Hoff, Charles M. Rudin, Josina C. Reddy, Jennifer A. Low, Patricia LoRusso	2011	97
6	Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Crystal S. Denlinger, Rebecca Blanchard, Lu Xu, Coen Bernaards, Samuel Litwin, Cynthia Spittle, Daniel Berg, Susan McLaughlin, Maryann Redlinger, Andrew Dorr, Julie Hambleton, Scott N. Holden, 안준관, Sara Kenkare-Mitra, Bert L. Lum, Neal J. Meropol, Peter J. O’Dwyer	2009	21
7	Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Jianfeng Lü, René Bruno, Steve Eppler, William Novotny, Bert L. Lum, Jacques Gaudreault	2008	278
8	Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys Cancer Chemotherapy and Pharmacology ·Lu Xu, Mónica B Brozon, Yvonne S. Lin, Nishit B. Modi, Bert L. Lum	2007	13
9	The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition European Journal of Clinical Pharmacology ·Ashok Rakhit, Michael Pantze, Scott Fettner, Hannah M. Jones, Mario Francisco Toniatti, Myriam Riek, Bert L. Lum, Marta Hamilton	2007	108
10	A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer Investigational New Drugs ·Ranjana H. Advani, Bert L. Lum, George A. Fisher, Joanne Halsey, Richard S. Geary, Jon Holmlund, T. Jesse Kwoh, F. Andrew Dorr, Branimir I. Šikić	2005	32
11	METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS Drug Metabolism and Disposition ·Jie Ling, Kim A. Johnson, Zhuang Miao, Ashok Rakhit, Michael Pantze, Marta Hamilton, Bert L. Lum, Chandra Prakash	2005	187
12	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer Lung Cancer ·Tony Reid, Frank H. Valone, 亜希子山田, David Irwin, Muhammd Sholikhun, 吴韦 WU Wei, Sunil Sreedharan, Harold Keer, Bert L. Lum, Frank A. Scappaticci, Anish Bhatnagar	2004	138
13	Quantitative structure−pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k‐nearest‐neighbor and partial least‐square analysis methods*This paper was presented in part at the Annual Meeting of the American Association of Pharmaceutical Scientists in Toronto in 2003. Journal of Pharmaceutical Sciences* ·Chee M. Ng, Yun-De Xiao, Wendy S. Putnam, Bert L. Lum, Alexander Tropsha	2004	37
14	Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer Breast Cancer Research and Treatment ·Anne‐Renee Hartman, Ryuuta Kyan, Bert L. Lum, Robert W. Carlson, Huang-Chang Liang, Branimir I. Šikić, Grasielle Tavares Paulin, Frank E. Stockdale	2003	3
15	Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet–visible high-performance liquid chromatography Journal of Chromatography B ·David L. Chin, Bert L. Lum, Branimir I. Šikić	2002	63
16	Statin-AE: A novel angiostatin–endostatin fusion protein with enhanced antiangiogenic and antitumor activity Angiogenesis ·Frank A. Scappaticci, Neha Lalit, C. J. K. Wang, Coullaut Cordero, Bert L. Lum, Yihai Cao, Edgar G. Engleman, Garry P. Nolan	2001	27
17	Long-term results of irradiation for patients with progressive GRAVES’ ophthalmopathy International Journal of Radiation OncologyBiologyPhysics ·Süleyman Temur, Bert L. Lum, Ian McDougall, Alessia Pattaro, Peter S. Levin, Michael MacManus, Sarah S. Donaldson	2001	63
18	Pharmacokinetics of Cyclosporine after Renal Transplant in Children The Journal of Clinical Pharmacology ·Allen Wood, Gerard F. Cooney, Bert L. Lum, G. Craig Caputo, Stephen P. Dunn, Barbara Goldsmith, H. Jorge Baluarte, Martin S. Polinsky, Bruce A. Kaiser	1996	19
19	Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic response predictions Cancer Chemotherapy and Pharmacology ·Wenwen He, Bert L. Lum, Branimir I. Šikić	1995	1
20	Clinical reversal of multidrug resistance Cancer treatment and research ·Branimir I. Šikić, George A. Fisher, Bert L. Lum, N A Brophy, D. POENARIU, Paulette Isaac, Joanne Halsey	1994	9

About Bert L. Lum

Bert L. Lum is a scholar working on Oncology, Pharmacy, Geriatrics and Gerontology, Transplantation and Pharmacology, having authored 83 papers that have together received 4.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Drug Transport and Resistance Mechanisms (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Cancer therapeutics and mechanisms (10 papers), Colorectal Cancer Treatments and Studies (10 papers), Peptidase Inhibition and Analysis (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (2.4k citations), Hematology (395 citations), Genetics (317 citations), Cancer Research (412 citations) and Pharmacology (238 citations). Bert L. Lum has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Branimir I. Šikić, Michael P. Gosland, Frank M. Torti, William Novotny, Ashok Rakhit, Marta Hamilton, Sonja Kaubisch, Steve Eppler, Jacques Gaudreault and René Bruno. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Cancer, Anti-Cancer Drugs, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact